The subgroup analysis revealed that DASH diet consumption could significantly reduce ALT in patients below 44 years old, baseline serum ALT above 30 IU/L, BMI below 30 kg/m2, and patients with NAFLD. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.